- Company
- Premium meningitis vaccine Bexsero lands in hospitals in KOR
- by Eo, Yun-Ho Nov 18, 2024 05:49am
- The next-generation meningococcal vaccine, ‘Bexsero’ can now be prescribed in general hospitals in Korea. According to industry sources, GSK Korea’s Bexsero, the first meningococcal B vaccine introduced to Korea, has passed the drug committees (DCs) of the Big 5 tertiary hospitals, including Samsung Medical Center, Seoul National Uni
- Company
- 'Tevimbra' can be prescribed at general hospitals
- by Eo, Yun-Ho Nov 18, 2024 05:49am
- 'Tevimbra,' a type of immune checkpoint inhibitor, is becoming more widely available for prescription at general hospitals. According to industry sources, BeiGene's PD-1 inhibitor Tevimbra (tislelizumab), which has applied for reimbursement for its esophageal cancer indication, has passed the drug committees (DC) of tertiary general hospi
- Policy
- HK Inno.N to distribute Tamiflu as Roche’s new partner
- by Lee, Tak-Sun Nov 18, 2024 05:49am
- HK Inno.N will be responsible for the domestic distribution of ‘Tamiflu Cap’ in addition to the distribution of the antiviral drug ‘Xofluza.’ The company is expected to gain external growth with the distribution of Tamiflu, which has an annual sales volume of KRW 15 billion. According to industry sources on the 15th, HK Inno.N se
- Company
- Demand rises for reform of the cancer drug reimb system
- by Moon, sung-ho Nov 18, 2024 05:49am
- With the presence of new anticancer drugs increasing in the clinical field, the pharmaceutical industry has been demanding the authorities apply a new reimbursement model in Korea. In addition to the existing immuno-oncology drugs, the emergence of antibody-drug conjugates (ADCs), which have proven effective in various cancers, has led to cal
- Company
- Six reimbursement revaluations fail in 4 years
- by Chon, Seung-Hyun Nov 15, 2024 05:49am
- Six items have been removed from the reimbursement list after reimbursement reevaluations during the past 4 years. Silymarin bilberry fruit dried powder, followed by itopride, failed the reimbursement reevaluations. Streptokinase - streptodornase, oxiracetam, and acetylcarnitine were also removed due to reimbursement reevaluation failures. Pharm
- Policy
- AZ’s Imjudo and Imfinzi both make reimbursement progress
- by Lee, Tak-Sun Nov 15, 2024 05:49am
- AstraZeneca (AZ) Korea’s ‘Imjudo Inj.’ Has passed the first step to reimbursement listing in Korea. Also, reimbursement standards for ‘Imfinzi Inj,’ which is seeking reimbursement expansions, were set. However, these are only the first steps to reimbursement. On the 13th, the Health Insurance Review and Assessment Service held the 8th
- Company
- Leqvio with 'twice-yearly treatment' set for mkt
- by Whang, byung-woo Nov 15, 2024 05:49am
- Leqvio is set to challenge the market with its superior drug tolerance, administered twice yearly, compared to existing treatments. According to the pharmaceutical industry on November 15, Novartis Korea launched the siRNA therapy Leqvio (inclisiran) on November 11. Lecvio is the first-in-class siRNA drug approved in South Korea. It is
- Opinion
- [Reporter’s View] Who’s to blame the new drug reimb delays
- by Eo, Yun-Ho Nov 15, 2024 05:49am
- Expedited approval of new drugs is one of the oldest issues in the pharmaceutical industry. Shortening the insurance reimbursement review period for drugs has been discussed almost every year, and in fact, the regulatory deadline is getting shorter and shorter. This is true for both the evaluation and negotiation stages of the Health Ins
- Company
- Hanmi's new bio drug 'Rolvedon' sales 88%↑ in the US mkt
- by Son, Hyung Min Nov 15, 2024 05:49am
- The U.S. sales of Rolvedon (Korean product name: Rolontis) have substantially increased. Hanmi Pharmaceutical's U.S. partnering company, Assertio, plans to expand market share by securing Rolvedon's indication for the same-day administration. According to Assertio on Novermber 14, Rolveron's sales in the U.S. market in Q3 were US$ 15 million
- Opinion
- [Reporter's View] The reality of drug shortage reports
- by Lee, Hye-Kyung Nov 14, 2024 05:52am
- Reports of shortages of oxytocin, an injectable drug used primarily as a labor inducer, have caused confusion in the obstetrics and gynecology field. Most obstetrics and gynecology centers that have a large number of expectant mother visits stock enough oxytocin to last 2-3 weeks, but JW Pharmaceuticals, which holds more than 70% of the pres
